Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

HCV sales down 18% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

2Q Revenues: $7.8 billion (-6%)

2Q Earnings: $3.5 billion (-22%)

YTD Revenues: $15.6 billion (-2%)

YTD Earnings: $7.1 billion (-20%)

Comments: Product sales for the quarter were $7.7 billion, down 5, with $4.9 billion in the U.S., down 13%, $1.6 billion in Europe, down 20%, $619 million in Japan compared to $62 million 2Q15, and $531 million in other locations, up 3%. HIV and other antiviral product sales were $3.1 billion, up 15% primarily due to increases in sales of tenofovir alafenamide (TAF) based products, Genvoya, Descovyand Odefsey. HCV product sales, which consist of Harvoni, Sovaldiand Epclusa, were $4.0 billion compared down 18% primarily due to a decline in sales of Harvoni. Other product sales, which include Letairis, Ranexa and AmBisome, were $525 million, up 6%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters